Your browser doesn't support javascript.
Adverse events following COVID-19 vaccination in Kwara State, North-central Nigeria.
Odeigah, Louis Okeibunor; Mutalub, Yahkub Babatunde; Agede, Olalekan Ayodele; Obalowu, Ismail A; Aiyetoro, Susan; Jimoh, Gafar A A.
  • Odeigah LO; Department of Family Medicine, College of Health Science University of Ilorin, Ilorin, Kwara State, Nigeria.
  • Mutalub YB; Department of Clinical Pharmacology and Therapeutics, College of Medical Sciences, Abubakar Tafawa Balewa University, Bauchi, Nigeria.
  • Agede OA; Department of Family Medicine Abubakar Tafawa Balewa University Teaching Hospital, Bauchi, Nigeria.
  • Obalowu IA; Department of Pharmacology and Therapeutics University of Ilorin, Ilorin, Nigeria.
  • Aiyetoro S; Department of Family Medicine, General Hospital Ilorin, Ilorin, Kwara State, Nigeria.
  • Jimoh GAA; Department of Pharmacy and Zonal Pharmacovigilance Center, University of Ilorin Teaching Hospital, Ilorin, Nigeria.
PLOS Glob Public Health ; 2(8): e0000835, 2022.
Article in English | MEDLINE | ID: covidwho-2039240
ABSTRACT
Safe and effective vaccination remains the mainstay of control of COVID-19 because there is still no universally recommended treatment. This strategy is however being threatened by vaccine hesitancy and resistance due to fear of adverse events and safety concerns. It is, therefore, necessary to study post-vaccination adverse events (AE) in various populations and geographical areas. The objective of this study was to analyze the adverse events following COVID-19 vaccination in five major immunization centers of Kwara State Nigeria. A retrospective descriptive study of the adverse events following AstraZeneca COVID-19 vaccination that were reported from five immunization centers of Kwara State, North-central Nigeria from March to July 2021 was carried out. Statistical Package for Social Science version 26 was used for analysis. Adverse event classification and severity were compared based on age, gender, and time to onset of adverse event and vaccine dose type using the Chi-square test. The incidence of COVID-19 vaccine AE was 1.6%. There was female predominance (51.6%) and a mean age of 41.6±13.7 years. Most of the AE (95.8%) were systemic and mild (81.1%) without a requirement for any therapeutic intervention. Fatal outcome was not reported in any of the AE and the time to outcome of AE was 2 days in most cases (45.3%). No significant association was found between the variables studied and the adverse event type and severity. The low incidence and mild nature of adverse events reported in this study will add to the body of knowledge regarding vaccine adverse events and may eventually impact vaccine uptake.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Topics: Vaccines Language: English Journal: PLOS Glob Public Health Year: 2022 Document Type: Article Affiliation country: Journal.pgph.0000835

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Topics: Vaccines Language: English Journal: PLOS Glob Public Health Year: 2022 Document Type: Article Affiliation country: Journal.pgph.0000835